Rapt Therapeutics Inc 's ROA from the third quarter of 2025 to the third quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Rapt Therapeutics Inc 's ROA in the third quarter of 2025?
Rapt Therapeutics Inc recorded a cumulative net loss of $-106 million during 12 months ending in the third quarter of 2025, resulting in a negative return on assets (ROA) of -55.19%.

However, within the Healthcare sector 593 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2025 quarter, so far to 4071, from total ROA ranking in the second quarter of 2025 at 4179.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter
Y / Y Total Assets Change	55.11 %	42.92 %	22.27 %	40.4 %	-45.47 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-106	-106	-117	-130	-107
Return On Assets (TTM)	-55.19 %	-60.25 %	-71.3 %	-83.8 %	-77.96 %
RAPT's Total Ranking	# 4071	# 4179	# 4352	# 5107	# 4480
Total Assets (TTM) in million	165	178	185	238	106
Seq. Total Assets Change	-7.32 %	-4.06 %	-21.99 %	123.62 %	-14.61 %
Seq. Net Income Change	-	-	-	-	-

RAPT's 5 Years Annual ROA >> Back to RAPT Management Effectiveness >> Compare RAPT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 260
Sector	# 594
Overall	# 4025

Return On Assets Statistics
High	Average	Low
141.48 %	-41.62 %	-82.22 %
(Mar 31 2020)		(Dec 31 2024)

Financial Statements
Rapt Therapeutics Inc 's Assets	$ 165 million	RAPT's Balance sheet
Rapt Therapeutics Inc 's Income	$ -18 million	Quarterly RAPT's Income Statement
RAPT's Income by Division		See RAPT's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	40.4 %	-35.22 %	31.51 %	66.96 %	40.62 %
Total Assets in million	238	169	261	199	119
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-130	-117	-84	-69	-53
Annual Return On Assets	-54.66 %	-69.02 %	-32.09 %	-34.84 %	-44.46 %

RAPT's 5 Years Annual ROA >> Back to RAPT Management Effectiveness >> Compare RAPT ROA to its Competitors

More Return On Assets Ratios
RAPT's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RAPT's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RAPT's Competitors
Subscribers only: Roa for Rapt Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for RAPT's Customers

You may also want to know
RAPT's Roi	RAPT's Inventory Turnover Ratio	RAPT's Growth Rates	RAPT's Dividend Comparisons
	RAPT's Profitability Ratios	RAPT's Asset Turnover Ratio	RAPT's Dividend Growth
RAPT's Roe	RAPT's Valuation Ratios	RAPT's Financial Strength Ratios	RAPT's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2025, within Healthcare Sector

ROA

Date modified: 2026-08-29T17:41:26+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.